Occupational asthma in a pharmaceutical worker exposed to hydralazine

B Perrin, J-L Malo, A Cartier, S Evans, J Dolovich

Abstract
A pharmaceutical worker developed asthma when exposed to hydralazine, an antihypertensive drug. The diagnosis of occupational asthma was supported by specific inhalation challenges, which produced a late asthmatic reaction and an increase in bronchial responsiveness. No evidence of an IgE or an IgG dependent mechanism could be found.

Occupational asthma due to pharmaceutical products in powder form among pharmacists, nurses, doctors, and workers at drug manufacturing plants has been described frequently. Several agents have been incriminated, as reviewed elsewhere. To the best of our knowledge, the antihypertensive drug hydralazine has never been linked to occupational asthma.

Case report
A 35 year old man had worked for four years as an operator at a pharmaceutical plant. Two years after beginning this work he noticed sneezing, dyspnoea, and wheezing on exposure to psyllium. Occupational asthma due to psyllium was excluded on the basis of negative results from an inhalation challenge test, in which the man was asked to tip psyllium from one tray to another in a challenge room. He showed no immediate skin reactivity to psyllium and the levels of specific IgE antibodies were normal (in contrast to occupational asthma due to psyllium in our experience). The subject also reported having symptoms of seasonal rhinitis since he was 18, which had become perennial in the preceding two years. The finding of bronchial hyperresponsiveness with a provocation concentration of methacholine causing a 20% fall in FEV₁ (PC₂₀) of 1.5 mg/ml led to a diagnosis of asthma in 1985.

The subject moved to another pharmaceutical company in 1985, where he also worked as an operator and where his exposure to hydralazine began, four years before his referral in 1989. In the preceding year he had noticed symptoms of sneezing, dyspnoea, and wheezing during the second day that hydralazine was being prepared. The symptoms appeared progressively and persisted for the four or five days when hydralazine was being made. He improved once the preparation of hydralazine had ended. Hydralazine was prepared every one to two months for four to five days. Skin prick tests with 15 common inhalant allergens and hydralazine diluted in phosphate buffered saline in concentrations of 0-1 and 1 mg/ml gave negative results. The total serum IgE level was 96 IU/l (normal). Tests for serum IgE antibodies to Dermatophagoides farinae, cat danders, and ragweed and grass pollens gave negative results.

Specific inhalation challenges were performed after four days away from work. The results are illustrated in the figure. On the first day the patient was exposed to lactose for 15 minutes with a new aerosolisation device, which keeps the concentration of particles under 10 mg/m³ (threshold limit value—short term exposure level or TLV-STEL). Baseline FEV₁ was 85% predicted. FEV₁ did not fluctuate by more than 10% during the day. The PC₂₀ for methacholine was 1.7 mg/ml, confirming the mild bronchial hyperresponsiveness that had been seen a few years before. On the second day the patient was exposed to hydralazine for seven minutes with the same apparatus: no fluctuations in FEV₁ of more than 10% were noticed during exposure or in the next few hours (a maximum increase in FEV₁ of 5% was observed). On the third day the subject was exposed to hydralazine for progressively increasing periods totalling 30 minutes. He experienced a late asthmatic reaction with cough and shortness of breath. A maximal fall in FEV₁ of 35-4% was recorded 270 minutes after exposure. Bronchoconstriction persisted for two hours. A bronchodilator was administered, with complete functional recovery. FEV₁ remained below 90% of the baseline value for three days after the late reaction, but had returned to baseline by eight days after the inhalation test, at which time the PC₂₀ was still low at 0-5 mg/ml. PC₂₀ was still reduced at 11 days (0.44 mg/ml) but had returned to baseline at 22 days (1.3 mg/ml).

Tests for IgE and IgG antibodies to hydralazine were performed by the radioallergosorbent test and the enzyme linked immunosorbent assay respectively by methods previously described. The results were negative.

Discussion
Our subject had a late reaction to inhalation challenges, suggesting that hydralazine can cause occupational asthma. The fact that he developed a late asthmatic reaction to a specific inhalation challenge with concentrations of particles below the TLV-STEL level makes an irritant reaction unlikely. The challenge was not blind and not repeated, so the possibility that some other agent—for example, aspirin—caused the reaction is a faint possibility. The fact that the reaction was prolonged in terms of changes in FEV₁ (possible interval 3-8 days) and PC₂₀ (possible interval 11-22 days) makes this unlikely.
Changes in FEV₁ on the control day of exposure to lactose and on the last day of exposure to hydralazine. BDT—inhaled salbutamol (200 μg).

No evidence for an immunological mechanism of the IgE or IgG type could be found. This is true of several pharmaceutical products that cause occupational asthma.² ¹

Although no case of occupational asthma due to hydralazine has been reported to our knowledge, Fueki—without giving any objective evidence—mentioned that it could cause rhinitis.⁹

We wish to thank Katherine Tallman for reviewing the manuscript.

---

Occupational asthma in a pharmaceutical worker exposed to hydralazine.

B Perrin, J L Malo, A Cartier, S Evans and J Dolovich

Thorax 1990 45: 980-981
doi: 10.1136/thx.45.12.980

Updated information and services can be found at:
http://thorax.bmj.com/content/45/12/980

These include:

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/